Oculis Appoints Dr. Frédéric Pilotaz as VP of Technology & Pharmaceutical Sciences ... 21 April, 2020
Oculis Expands Portfolio with a Novel Phase II-stage Anti-TNF alpha Antibody Fragment 04 January, 2019